These data demonstrate the essential role that HRR function plays in the anti-tumor activity of PARPi since all but one of the patients with mCRPC with BRCA2 homozygous deletion had, after initial response to PARPi, copy-number data suggesting the presence of a BRCA2 hemizygous deletion at disease progression. This evidence concerns the gene BRCA2 and neoplasm.